|
Market Closed -
OTC Markets
15:19:24 2026-10-01 EDT
|
5-day change | 1st Jan Change | ||
| 22.77 USD | -5.12% |
|
-6.62% | -7.44% |
| 07:52am | GSK plc : JP Morgan reiterates its Sell rating | ZD |
| 09-30 | European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading | MT |
| Market Cap | 71.93B 95.02B 84.4B 78.93B 135B 9,149B 137B 955B 370B 4,659B 357B 349B 14,966B | P/E 2026 * |
13.9x | P/E 2027 * | 11.5x |
|---|---|---|---|---|---|
| Enterprise Value | 93.17B 123B 109B 102B 175B 11,851B 178B 1,237B 479B 6,036B 462B 452B 19,386B | EV / Sales 2026 * |
2.75x | EV / Sales 2027 * | 2.55x |
| Free-Float |
92.75% | Yield 2026 * |
3.88% | Yield 2027 * | 4.17% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Deutsche Boerse AG
| GS71 | Delayed | |
|
OTC Markets
| GLAXF | Delayed | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
Börse Stuttgart
| GS71 | Delayed |
Last Transcript: GSK plc
| 07:52am | GSK plc : JP Morgan reiterates its Sell rating | ZD |
| 09-29 | GSK plc : Gets a Neutral rating from Deutsche Bank | ZD |
| 09-29 | GSK plc : Jefferies keeps its Buy rating | ZD |
| 09-18 | GSK plc : Deutsche Bank remains Neutral | ZD |
| 09-17 | GSK plc : UBS is Neutral | ZD |
| 1 day | -5.13% | ||
| 1 week | -6.62% | ||
| Current month | -5.12% | ||
| 1 month | -8.84% | ||
| 3 months | -11.64% | ||
| 6 months | -12.59% | ||
| Current year | -7.44% |
| 1 week | 22.77 |  | 24.38 |
| 1 month | 22.77 | | 25.65 |
| Current year | 22.75 | | 31.48 |
| 1 year | 20.78 | | 31.48 |
| 3 years | 15.54 | | 31.48 |
| 5 years | 13.48 | | 31.48 |
| 10 years | 13.48 | | 31.48 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.12% | -6.62% | - | - | 97.46B | |
| -0.62% | -2.71% | +39.30% | +113.61% | 1,031B | |
| -2.30% | -4.44% | +39.03% | +66.72% | 638B | |
| -0.63% | -1.96% | +6.36% | +75.33% | 462B | |
| -1.03% | -2.82% | +59.56% | +40.23% | 359B | |
| -0.03% | -3.91% | +34.28% | +39.35% | 335B | |
| -1.58% | +0.39% | +17.92% | +25.77% | 273B | |
| -2.02% | -3.20% | +7.60% | +8.38% | 253B | |
| -3.38% | +0.30% | +36.44% | +52.93% | 228B | |
| -1.04% | -1.46% | +32.70% | +99.06% | 185B | |
| Average | -1.60% | -0.36% | +30.36% | +57.93% | 418.21B | |
| Weighted average by Cap. | -1.12% | -0.35% | +32.51% | +69.53% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.92B 44.81B 39.8B 37.22B 63.86B 4,315B 64.74B 450B 174B 2,197B 168B 165B 7,058B | 35.5B 46.9B 41.65B 38.95B 66.83B 4,515B 67.75B 471B 182B 2,300B 176B 172B 7,386B |
| Net income | 5.19B 6.86B 6.09B 5.7B 9.77B 660B 9.91B 68.92B 26.68B 336B 25.75B 25.19B 1,080B | 6.21B 8.2B 7.29B 6.81B 11.69B 790B 11.85B 82.43B 31.91B 402B 30.8B 30.13B 1,292B |
| Net Debt | 21.24B 28.06B 24.93B 23.31B 39.99B 2,702B 40.54B 282B 109B 1,376B 105B 103B 4,420B | 18.52B 24.46B 21.73B 20.32B 34.86B 2,355B 35.34B 246B 95.16B 1,200B 91.85B 89.86B 3,853B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-01 | US$22.77 | -5.12% | 1,100 |
| 26-09-28 | US$24.00 | -1.58% | 378 |
| 26-09-25 | US$24.39 | +0.53% | 250 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GLAXF Stock
Select your edition
All financial news and data tailored to specific country editions
